European Union´s Horizon 2020 – Lipum2019-01-31T10:20:32+00:00


Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

1406, 2019

Kallelse till årsstämma i Lipum AB

June 14th, 2019|

Aktieägarna i Lipum AB, org. nr. 556813-5999 (“Lipum”), kallas härmed till årsstämma fredagen den 28 juni 2019, kl. 09:00 på Tvistevägen 48C i Umeå. […]

1705, 2019

Getting roasted by investors

May 17th, 2019|

As a Horizon 2020 beneficiary we are invited to the SME Instrument Phase 2 Welcome Day organized by the European Innovation Council (EIC) Pilot in Brussels, May 22-23. Besides business networking the agenda includes: “Get roasted by investors – ready to go?”, “Success story from SME Instrument Innovator” and “Learn [...]

2103, 2019

Lipum attracts interest from life science leaders

March 21st, 2019|

Lipum is attending two significant events in Vienna next week. At the RESI Europe and the BIO-Europe Spring meetings we will meet with key decision makers from the pharma and venture capital segments. These events take place March 25-27 and provides an opportunity to meet, please contact us and learn [...]

1903, 2019

Lipum and Abzena sign integrated CMC agreement

March 19th, 2019|

Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory [...]

European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€